Inirapatidin Tablet 10mg

Adult dosage

1. Short-term treatment of gastric ulcers: The usual dose is 10mg of lafutidine orally twice daily, in the morning and before bedtime. In clinical trials with treatment for up to 8 weeks, most ulcers healed within 8 weeks, although the healing period may occasionally vary by patient. 2. Short-term treatment of duodenal ulcers: The usual dose is 10mg of lafutidine orally twice daily, in the morning and before bedtime. In clinical trials with treatment for up to 6 weeks, most ulcers healed within 6 weeks, although the healing period may occasionally vary by patient. 3. Improvement of gastric mucosal lesions in acute and chronic gastritis: The usual dose is 10mg of lafutidine orally once daily before bedtime. In clinical trials with treatment for up to 2 weeks, most lesions healed within 2 weeks, although the healing period may occasionally vary by patient. 4. Combination antibiotic therapy for patients with peptic ulcers infected with Helicobacter pylori: Administer lafutidine 20mg, clarithromycin 500mg, and amoxicillin 1000mg twice daily for 7 or 14 days. 5. Premedication before anesthesia: The usual dose is 10mg of lafutidine per dose, administered orally twice (before bedtime on the day before surgery and 2 hours before anesthesia on the day of surgery). 6. Treatment of reflux esophagitis: Administer lafutidine 10mg per dose orally twice daily.

This medication should not be used by those allergic to any of its ingredients. Additionally, as it contains lactose, individuals with genetic issues such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should avoid taking this medication. Patients with a history of drug allergies or issues with liver or kidney function, those undergoing dialysis, and elderly patients should be particularly cautious when using this medication. This medication can rarely cause severe allergic reactions, liver dysfunction, and significant side effects such as a decrease in blood cell count, so symptoms should be closely monitored, and if any abnormalities occur, usage should be discontinued immediately and a doctor consulted. Mild side effects such as constipation, diarrhea, headache, dizziness, and fatigue may occur in some patients, so it is important to monitor one’s condition closely. If a malignant tumor is suspected, as this medication may conceal symptoms or delay diagnosis, comprehensive tests should be conducted, and if diagnosed with malignant gastric cancer, this medication should be discontinued. During treatment, regular monitoring of the patient's blood, liver, and kidney functions should be conducted while using the minimum effective dose, and if there is no effect, a different treatment method should be adopted. Elderly patients may have reduced bodily functions and should take this medication with careful adjustments to dosage and administration intervals. For patients undergoing dialysis, blood drug concentration may increase, so they should start with a low dose and proceed cautiously. Pregnant women or those who may become pregnant should use this medication only under a doctor's judgment, and nursing mothers are advised against taking this medication since it can be excreted in breast milk. Safety in children has not been established, so it should be used cautiously in pediatric patients. This medication should be kept out of the reach of children and stored in its original container to maintain drug quality and prevent misuse.

• Shock
• symptoms of anaphylaxis
• facial pallor
• hypotension
• generalized rash
• dyspnea
• liver dysfunction
• jaundice
• agranulocytosis
• pharyngitis

This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle